Back to search results

Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Pediatric Cancers · Solid Tumor Pediatric

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • King Chulalongkorn Memorial Hospital, Bangkok, Pathumwan, Thailand

    Contact: Study coordinator (Piti Techavichit, MD) · piti.t@chula.ac.th · +66817515363
    Contact: Study coordinator (Kanhatai Chiengthong, MD) · kanhatai.c@chula.ac.th · +66814430961
    Contact: Principal Investigator (Piti Techavichit, MD)
    Koramit Suppipat, MD (Sub-investigator)
    Kanhatai Chiengthong, MD (Sub-investigator)
    Supannikar Tawinwung, PhD (Sub-investigator)
    Chantiya Chanswanghuwana, MD (Sub-investigator)
Study leads

  • Piti Techavichit, Associate Professor, MD

    Principal Investigator

    Chulalongkorn University

View source on ClinicalTrials.gov(opens in a new tab)